Cargando…
Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
Dasatinib is a potent dual Abl/Src inhibitor approved for treatment of Ph-positive leukemias. At a once-daily dose and a relatively short half-life of 3-5 hours, tyrosine kinase inhibition is not sustained. However, transient inhibition of K562 leukemia cells with a high-dose pulse of dasatinib or l...
Autores principales: | Fei, Fei, Stoddart, Sonia, Müschen, Markus, Kim, Yong-mi, Groffen, John, Heisterkamp, Nora |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038787/ https://www.ncbi.nlm.nih.gov/pubmed/20111071 http://dx.doi.org/10.1038/leu.2009.302 |
Ejemplares similares
-
Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia
por: Feldhahn, Niklas, et al.
Publicado: (2012) -
Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
por: Kaur, Pavinder, et al.
Publicado: (2007) -
BCL6 enables Ph(+) acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition
por: Duy, Cihangir, et al.
Publicado: (2011) -
BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy
por: Yamada, Chika, et al.
Publicado: (2021) -
Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)